These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31305414)

  • 1. Effectiveness of mesalazine to treat irritable bowel syndrome: A meta-analysis.
    Zhang FM; Li S; Ding L; Xiang SH; Zhu HT; Yu JH; Xu GQ
    Medicine (Baltimore); 2019 Jul; 98(28):e16297. PubMed ID: 31305414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
    Bafutto M; Almeida JR; Leite NV; Oliveira EC; Gabriel-Neto S; Rezende-Filho J
    Arq Gastroenterol; 2011; 48(1):36-40. PubMed ID: 21537540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
    Lam C; Tan W; Leighton M; Hastings M; Lingaya M; Falcone Y; Zhou X; Xu L; Whorwell P; Walls AF; Zaitoun A; Montgomery A; Spiller R
    Gut; 2016 Jan; 65(1):91-9. PubMed ID: 25765462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
    Castro Tejera V; Öhman L; Aabakken L; Fellström B; Hausken T; Hovde Ø; Hreinsson JP; Lindberg G; Venge P; Simrén M; Törnblom H
    Aliment Pharmacol Ther; 2022 Sep; 56(6):968-979. PubMed ID: 35942522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome.
    Wang Y; Hu Y; Shi P
    BMC Gastroenterol; 2024 Jul; 24(1):217. PubMed ID: 38970007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis.
    Li X; Li B; Zhang J; Chen T; Wu H; Shi X; Ma J; Qin J; Tang X; Wang F
    Medicine (Baltimore); 2021 Jan; 100(4):e24361. PubMed ID: 33530231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised controlled trial of mesalazine in IBS.
    Barbara G; Cremon C; Annese V; Basilisco G; Bazzoli F; Bellini M; Benedetti A; Benini L; Bossa F; Buldrini P; Cicala M; Cuomo R; Germanà B; Molteni P; Neri M; Rodi M; Saggioro A; Scribano ML; Vecchi M; Zoli G; Corinaldesi R; Stanghellini V
    Gut; 2016 Jan; 65(1):82-90. PubMed ID: 25533646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome.
    Connell M; Shin A; James-Stevenson T; Xu H; Imperiale TF; Herron J
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13427. PubMed ID: 30069978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis.
    Yang R; Jiang J; Ouyang J; Zhao Y; Xi B
    Clin Nutr ESPEN; 2024 Apr; 60():362-372. PubMed ID: 38479936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
    Yuan F; Ni H; Asche CV; Kim M; Walayat S; Ren J
    Curr Med Res Opin; 2017 Jul; 33(7):1191-1197. PubMed ID: 28166427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials.
    Niu HL; Xiao JY
    Int J Surg; 2020 Mar; 75():116-127. PubMed ID: 32014597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome.
    Quartero AO; Meineche-Schmidt V; Muris J; Rubin G; de Wit N
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003460. PubMed ID: 15846668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.
    Goodoory VC; Tuteja AK; Black CJ; Ford AC
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):243-251.e5. PubMed ID: 36858143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A meta-analysis of probiotics for the treatment of irritable bowel syndrome].
    Hu Y; Tao L; Lyu B
    Zhonghua Nei Ke Za Zhi; 2015 May; 54(5):445-51. PubMed ID: 26080826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lactulose for the treatment of irritable bowel syndrome.
    Chen HB; Su XY
    Medicine (Baltimore); 2019 Sep; 98(39):e17295. PubMed ID: 31574851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.